PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 25, 2012CNS Neuroscience & Therapeutics8 citationsOpen Access

Acute Stroke Management in Patients Taking Dabigatran

View Full Paper
RBRaf BrounsRHRobbert‐Jan Van HooffASAnn De Smedt

Key Result

This review provides pragmatic approaches for individualized decision-making regarding hemostatic therapy and reperfusion strategies in acute stroke patients taking dabigatran.

Structured PICO

P
Population
Patients taking dabigatran who experience acute stroke (intracerebral hemorrhage or acute ischemic stroke)
I
Intervention
Hemostatic therapy and reperfusion strategies

This review provides pragmatic approaches for individualized decision-making regarding hemostatic therapy and reperfusion strategies in acute stroke patients taking dabigatran.

Abstract

Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-based guidelines for management of intracerebral hemorrhage and acute ischemic stroke in patients taking this drug are nonexistent. This review summarizes current knowledge on key pharmacological features and the assessment of dabigatran activity. Pragmatic approaches are provided for individualized decision taking with regard to hemostatic therapy and reperfusion strategies in acute stroke patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Brouns et al. (2012) conducted a review in Acute stroke (intracerebral hemorrhage and acute ischemic stroke) in patients taking dabigatran. Hemostatic therapy and reperfusion strategies was evaluated. This review provides pragmatic approaches for individualized decision-making regarding hemostatic therapy and reperfusion strategies in acute stroke patients taking dabigatran.

synapsesocial.com/papers/6a84647f064c65267cc6ca5chttps://doi.org/10.1111/j.1755-5949.2012.00329.x
Ask AI
Helpful
Bookmark
Share
View Full Paper